Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis

BACKGROUND: Little data exist on the use of direct oral anticoagulant (DOAC) factor Xa inhibitors for submassive pulmonary embolism (PE) after catheter-directed thrombolysis (CDT). The objective of this evaluation was to determine whether the transition from parenteral anticoagulation to DOACs for s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Appl Thromb Hemost
Autori principali: Groetzinger, Lara M., Miller, Taylor J., Rivosecchi, Ryan M., Smith, Roy E., Gladwin, Mark T., Rivera-Lebron, Belinda N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6714714/
https://ncbi.nlm.nih.gov/pubmed/29455567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029618755311
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi